Big biotech, Emergent BioSolutions has signed a contract with the National Institute of Allergy and Infectious Diseases to develop a dry formulation of NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant).
AV7909, the company’s next generation anthrax vaccine candidate.
This five-year contract, valued at up to $29 million, provides funding for manufacturing and non-clinical activities through the preparation of an Investigational New Drug application to the U.S. Food and Drug Administration.
The dry formulation of NuThrax is intended to increase stability of the vaccine candidate at ambient and higher temperatures, with the objective of eliminating the need for cold chain during shipping and storage.
For further deal information visit Current Agreements (subscription required)
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity